IRX-2 2015A: A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage III or IV Squamous Cell Carcinoma of the Oral Cavity

Grants and Contracts Details

StatusFinished
Effective start/end date1/25/167/26/23

Funding

  • PPD Development Inc: $117,631.00